Intrexon Corporation (XON) : Fridays money flow data in Intrexon Corporation (XON) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $1.12 million, whereas, $0.89 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.26, in favor of the bulls. The total money flow into the stock was $0.23 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $0 million. The total value of block trades done on upticks was $0 million. Intrexon Corporation (XON) fell $0.08 and traded at $25.21, down -0.32% for the day, over previous days close. On a weekly basis, the shares are -3.48% over the previous weeks close.
The company Insiders own 55.1% of Intrexon Corporation shares according to the proxy statements. Institutional Investors own 84.08% of Intrexon Corporation shares.
In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the officer (SVP-Corporate Development) of Intrexon Corp, Nimrodi Nir had purchased shares worth of $104,480 in a transaction dated on August 29, 2016. A total of 4,000 shares were purchased at a price of $26.12 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Intrexon Corporation (NYSE:XON): The stock opened at $25.38 and touched an intraday high of $25.76 on Friday. During the day, the stock corrected to an intraday low of $24.96, however, the bulls stepped in and pushed the price higher to close in the green at $25.33 with a gain of 0.16% for the day. The total traded volume for the day was 966,252. The stock had closed at $25.29 in the previous trading session.
Intrexon Corporation (XON) : During the past 4 weeks, traders have been relatively bearish on Intrexon Corporation (XON), hence the stock is down -11.66% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.51% relative to the S&P 500. The 4-week change in the price of the stock is -11.77% and the stock has fallen -3.02% in the past 1 week.
Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.